KROS Keros Therapeutics, Inc.: institutional ownership and insider trading
142 funds reported holding $233M of Keros Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net sold $3.35M, with 14 new positions and 30 funds selling out; over the last 12 months insiders bought $75.8K and sold $523K on the open market.
Famous investors holding KROS
- Renaissance Technologies (Renaissance Technologies): $3.84M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $4.39M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $2.86M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $2.64M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $1.98M, 0.0% of the portfolio
Largest institutional holders of KROS
- VANGUARD GROUP INC — $31.1M
- BlackRock, Inc. (BLK) — $29.9M
- Nantahala Capital Management, LLC — $15.1M
- AQR CAPITAL MANAGEMENT LLC — $10.4M
- VANGUARD CAPITAL MANAGEMENT LLC — $8.92M
- ORBIMED ADVISORS LLC — $8.12M
- FEDERATED HERMES, INC. (FHI) — $7.49M
- VANGUARD PORTFOLIO MANAGEMENT LLC — $6.98M
- MACKENZIE FINANCIAL CORP — $6.72M
- Madison Avenue Partners, LP — $6.70M
Recent KROS insider trades
- Aug 18, 2026: Newton Charles W. sold 551 shares ($5.68K)
- Aug 18, 2026: Lerner Lorena Raquel sold 3,568 shares ($36.7K)
- Aug 18, 2026: Cho Esther sold 4,485 shares ($46.2K)
- Aug 18, 2026: Tanini Annita sold 1,224 shares ($12.6K)
5%+ owners
- BlackRock, Inc.: 8.4% (Schedule 13G/A, filed Jul 29, 2026)
- Nantahala Capital Management, LLC: 6.9% (Schedule 13G, filed May 15, 2026)
- BlackRock Portfolio Management LLC: 5.7% (Schedule 13G, filed Jul 17, 2026)